Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
According to CNN, Califf is being vetted by the administration of Joe Biden, who served as vice president to Obama.
Biopharma and life sciences companies strengthen their leadership teams and executive boards with these Movers & Shakers.
On October 6, 2021, Bristol Myers Squib and Celgene terminated the original deal related to Abraxane and gave BeiGene 180 days of notice that it was withdrawing Abraxane from the deal.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Transition Bio named Gregory Miller as chief executive officer, Prof. Tuomas Knowles as chief technology officer and Martin Kulander as chief operating officer, among several others.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.
Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science.
Rectify emerged with a goal to develop disease-modifying precision therapies that will restore ABC transporter function in order to address the underlying cause of serious genetic disease.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.